Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Consensus Recommendation of “Hold” from Brokerages

Posted by George Bondi on Sep 30th, 2026

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) have been assigned an average recommendation of “Hold” from the eleven brokerages that are covering the firm, MarketBeat reports. Nine investment analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating on the company.

ZLDPF has been the topic of a number of recent analyst reports. Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Berenberg Bank lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. Jefferies Financial Group cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Barclays cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday, June 4th.

Check Out Our Latest Research Report on Zealand Pharma A/S

Zealand Pharma A/S Price Performance

ZLDPF stock opened at $41.99 on Friday. The firm has a 50 day simple moving average of $46.93 and a two-hundred day simple moving average of $46.36. The stock has a market cap of $3.00 billion, a PE ratio of 6.96 and a beta of 0.89. Zealand Pharma A/S has a one year low of $35.93 and a one year high of $83.12. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.98 and a quick ratio of 13.98.

About Zealand Pharma A/S

(Get Free Report)

Zealand Pharma A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing peptide-based medicines. The company’s research programs address serious and underserved conditions, particularly metabolic diseases, gastrointestinal disorders and rare diseases. Zealand combines proprietary peptide technologies with drug-development expertise to create therapies designed to improve treatment outcomes and patient convenience.

Zealand’s commercial portfolio includes Zegalogue (dasiglucagon), an injectable treatment for severe hypoglycemia in people with diabetes.